

### Cibinqo (abrocitinib)

#### Disclaimer

*Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.*

*Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.*

#### Summary

Atopic dermatitis (AD) is a chronic inflammatory skin disorder that affects approximately 10% of adults and 20% of children worldwide. It is characterized by intense itching, redness, and eczematous lesions, which can be accompanied by skin dryness, scaling, and thickening. The clinical course of AD is characterized by chronic, relapsing episodes over months to years. In mild cases, one may experience intermittent flares that may or may not clear without the use of pharmacological intervention. In more moderate and severe cases, flares rarely clear without pharmacological intervention/therapy. The severity of AD can be classified as mild, moderate, or severe, depending on the extent and intensity of skin inflammation, as well as the impact on the patient's quality of life. Moderate-to-severe AD is defined by the presence of extensive or widespread lesions, intense pruritus, and significant impairment of daily activities, sleep, and mood.

Treatment options for moderate-to-severe AD involve a combination of topical and systemic therapies, tailored to the individual patient's needs and preferences. The goal of treatment is to control inflammation, relieve itching, restore the skin barrier, prevent flares, and improve quality of life.

- Topical treatments for moderate-to-severe AD include corticosteroids, calcineurin inhibitors, and phosphodiesterase-4 (PDE4) inhibitors. These drugs act by reducing inflammation and pruritus and promoting skin healing. However, their long-term use may be limited by adverse effects, such as skin atrophy, telangiectasias, or the potential risk of skin infections or malignancies.

- Systemic treatments for moderate-to-severe AD are reserved for patients with inadequate response or contraindications to topical therapies, or those with severe or rapidly worsening disease. The most commonly used systemic agents include oral immunosuppressants, such as cyclosporine, methotrexate, or mycophenolate mofetil, and biologic agents, such as dupilumab, which targets the interleukin-4 (IL-4)/interleukin-13 (IL-13) pathway.

Cibinqo (abrocitinib) is indicated for the treatment of adults and those 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when the use of those therapies is inadvisable.

*Limitations of Use: Cibinqo (abrocitinib) is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.*

## Definitions

“Atopic Dermatitis” also known as eczema is a chronic skin condition that makes a person’s skin red, itchy and scaly. Atopic dermatitis (AD) often begins during childhood and persists into adulthood. Some people experience occasional flares followed by periods of improvement or a “waxing and waning” course of the disease.

“Biologics” are a type of medication that are designed to target specific parts of the immune system. Some biologics, such as Dupixent, Adbry, and Rinvoq, are used in the treatment of moderate to severe atopic dermatitis.

“Body Surface Area (BSA%)” is a measure of the total area involved by plaques in relation to the total body surface area. There are a number of different methods, however most clinical trials on plaque psoriasis use the “handprint method”, where the patient’s actual palm/hand size is estimated as 1% of BSA. The head and neck, upper extremities, trunk, and lower extremities (including buttocks) typically correspond to approximately 10%, 20%, 30% and 40% of the BSA, respectively.

“Interleukin (IL)-13 cytokine” is a protein secreted by certain cells of the immune system that affects many aspects of chronic airway inflammation.

“Janus kinase 1 (JAK1) inhibitor” is a type of medication that functions by inhibiting the activity of one or more enzymes in the Janus kinase family. This action helps to reduce the inflammatory response that underlies conditions like atopic dermatitis.

“Topical Corticosteroids (TCS)” are steroid medications applied to the skin. They are used to reduce inflammation and suppress the immune response in conditions like atopic dermatitis.

### Medical Necessity Criteria for Initial Authorization

The Plan considers Cibinqo (abrocitinib) medically necessary when ALL of the following criteria are met:

1. The medication is prescribed by or in consultation with a dermatologist, allergist, or immunologist; *AND*
2. The member is 12 years of age or older; *AND*
3. The member has a documented diagnosis of moderate to severe atopic dermatitis *AND ONE* (1) of the following:
  - a. Involvement of ( $\geq$ ) 10% or more of body surface area; *or*
  - b. Involvement of sensitive body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas); *AND*
4. The member is unable to use, or has adequately tried and failed ALL of the following topical therapies for at least 8 weeks each in the past 365 days:
  - a. At least one (1) topical corticosteroid (TCS) from medium potency (group III to IV) classes to higher potencies (groups I to II) classes (see Table 2); *and*
  - b. Tacrolimus ointment; *and*
  - c. Eucrisa (crisaborole) [require members be unable to use, or has tried and failed a medium or higher potency TCS within the past 180 days]; *AND*
5. Cibinqo (abrocitinib) will not be used concomitantly with other JAK inhibitors, biologics (e.g., Dupixent, Adbry, or Rinvoq) in the treatment of atopic dermatitis; *AND*
6. Cibinqo (abrocitinib) is being prescribed within the manufacturer's published dosing guidelines or falls within dosing guidelines found in a compendia of current literature; *AND*
7. Clinical chart documentation is provided for review to validate the above listed requirements.

If the above prior authorization criteria are met, Cibinqo (abrocitinib) will be approved for up to 4-months.

### Medical Necessity Criteria for Reauthorization

Reauthorization for up to 12 months may be provided for members 12 years of age or older when recent chart documentation (within the past 4-months) is provided showing ALL of the following criteria are met:

1. The member is responding positively to Cibinqo (abrocitinib) treatment based upon the prescriber's assessment as demonstrated by ONE (1) of the following:
  - a. decreased disease activity (e.g., a reduction in BSA%); *or*
  - b. symptomatic improvement (e.g., redness, itching, oozing/crusting); *AND*
2. Cibinqo (abrocitinib) will not be used concomitantly with other JAK inhibitors, biologics (e.g., Dupixent, Adbry, or Rinvoq) in the treatment of atopic dermatitis; *AND*
3. Cibinqo (abrocitinib) is being prescribed within the manufacturer's published dosing guidelines or falls within dosing guidelines found in a compendia of current literature.

### Experimental or Investigational / Not Medically Necessary

Cibinqo (abrocitinib) for any other indication apart from atopic dermatitis is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, or unproven. Non-covered indications include, but are not limited to, the following:

- Chronic Prurigo / Prurigo Nodularis / Pruritus / Pruritus Chronic / Skin Diseases.
- Granuloma annulare lesions.
- Psoriasis.
- Psoriasis Vulgaris (Plaque Psoriasis).
- Sarcoidosis.
- Use for dual therapy with other JAK inhibitors or biologics (e.g., Dupixent, Adbry, or Rinvoq).
- Use as a preventative agent for the development of skin conditions.

### Appendix

Table 1: Dosage, Retreatment, and Other Considerations

Indication	Initial dose	Subsequent dose	Additional Considerations
Moderate to severe atopic dermatitis	100 mg PO once daily	If an adequate response is not achieved after 12 weeks, consider increasing the dose to 200 mg PO once daily	Complete any necessary immunizations, including herpes zoster vaccinations, prior to Cibinqo (abrocitinib) initiation
Adults who are CYP2C19 poor metabolizers	50 mg PO once daily	If an adequate response is not achieved after 12 weeks, consider increasing the dose to 100 mg PO once daily. Discontinue use of the drug if an adequate response is not achieved with the 100 mg dose	N/A
Renal Impairment: Mild (60 - 89 mL/minute eGFR)	100 mg PO once daily	If an adequate response is not achieved after 12 weeks, the dose of CIBINQO can be doubled	N/A
Renal Impairment: Moderate (30 - 59 mL/minute eGFR)	50 mg PO once daily	If an adequate response is not achieved after 12 weeks, the dose of CIBINQO can be doubled	N/A
Renal Impairment: Severe† (15 - 29 mL/minute eGFR)	Not recommended for use	N/A	N/A

End-Stage Renal Disease† (ESRD) (<15 mL/minute eGFR)	Not recommended for use	N/A	N/A
Hepatic Impairment: Severe	Not recommended for use	N/A	N/A
Taking strong inhibitors of CYP2C19	50 mg PO once daily	If an adequate response is not achieved after 12 weeks, consider increasing the dose to 100 mg PO once daily. Discontinue therapy if inadequate response is seen after dosage increase to 100 mg once daily	N/A

†Severe Renal Impairment and End-Stage Renal Disease include patients on renal replacement therapy.

Table 2: Topical Corticosteroid Potency

*NOTE: The following chart is only for approximate comparative purposes. Please check product-specific information to best assess product potency, which can also be affected by a multitude of factors (e.g., formulation, site of application, member and disease-specific factors)*

Group	Potency	Steroid	Strength	Dosage Form
I	Very High	Betamethasone dipropionate (augmented)	0.05%	Gel, Lotion, and Ointment
		Clobetasol propionate	0.05%	Cream, Emollient Cream, Foam, Gel, Lotion, Ointment, Spray, and Solution
		Diflorasone diacetate	0.05%	Ointment
		Fluocinonide	0.1%	Cream
		Flurandrenolide	0.05%	Tape
		Halobetasol propionate	0.05%	Cream, Foam, Lotion and Ointment
II	High	Amcinonide	0.1%	Ointment
		Betamethasone dipropionate (augmented)	0.05%	Cream
		Betamethasone dipropionate	0.05%	Ointment

		Clobetasol propionate	0.025%	Cream
		Desoximetasone	0.25%	Cream, Ointment and Spray
		Desoximetasone	0.05%	Gel
		Diflorasone diacetate	0.05%	Cream, and Emollient Cream
		Fluocinonide	0.05%	Cream, Gel, Ointment, and Solution
		Halcinonide	0.1%	Cream, Ointment, and Solution
		Halobetasol propionate	0.01%	Lotion
III	Upper Medium	Amcinonide	0.1%	Cream and Lotion
		Betamethasone dipropionate	0.05%	Cream
		Betamethasone valerate	0.12%	Foam
		Betamethasone valerate	0.1%	Ointment
		Fluocinonide	0.05%	Emollient Cream
		Fluticasone propionate	0.005%	Ointment
		Mometasone furoate	0.1%	Ointment
		Triamcinolone acetonide	0.5%	Cream
IV	Medium	Betamethasone dipropionate	0.05%	Spray
		Clocortolone pivalate	0.1%	Cream
		Desoximetasone	0.05%	Cream and Ointment
		Fluocinolone acetonide	0.025%	Ointment
		Flurandrenolide	0.05%	Ointment
		Fluticasone propionate	0.05%	Cream
		Hydrocortisone valerate	0.2%	Ointment
		Mometasone furoate	0.1%	Cream, Lotion, and Solution
		Triamcinolone acetonide	0.1%	Cream, Dental Paste, Ointment, and Spray
V	Lower Medium	Betamethasone dipropionate	0.05%	Lotion

		Betamethasone valerate	0.1%	Cream
		Desonide	0.05%	Gel and Ointment
		Fluocinolone acetonide	0.025%	Cream
		Fluocinolone acetonide	0.01%	Shampoo
		Flurandrenolide	0.05%	Cream and Lotion
		Fluticasone propionate	0.05%	Lotion
		Hydrocortisone butyrate	0.1%	Cream, Lotion, Ointment, and Solution
		Hydrocortisone probutate	0.1%	Cream
		Hydrocortisone valerate	0.2%	Cream
		Prenicarbate	0.1%	Emollient Cream and Ointment
		Triamcinolone acetonide	0.1%	Lotion
		Triamcinolone acetonide	0.025%	Ointment
VI	Low	Alclometasone dipropionate	0.05%	Cream and Ointment
		Betamethasone valerate	0.1%	Lotion
		Desonide	0.05%	Cream, Lotion, and Foam
		Fluocinolone acetonide	0.01%	Cream, Oil, Shampoo and Solution
		Triamcinolone acetonide	0.025%	Cream and Lotion
VII	Lowest	Hydrocortisone acetate	1% to 2%	Cream and Ointment
		Hydrocortisone base	0.5% to 2.5%	Cream, Gel, Lotion, Ointment, Solution, and Spray

## References

1. AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel; Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, Frazier WT, Greenhawt M, Huynh J, Kim E, LeBovidge J, Lind ML, Lio P, Martin SA, O'Brien M, Ong PY, Silverberg JI, Spergel JM, Wang J, Wheeler KE, Guyatt GH; Patient Groups: Global Parents for Eczema Research; Capozza K; National Eczema Association; Begolka WS; Evidence in Allergy Group; Chu AWL, Zhao IX, Chen L, Oykman P, Bakaa L; AAAAI/ACAAI Joint Task Force on Practice Parameters; Golden D, Shaker M, Bernstein JA, Greenhawt M, Horner CC, Lieberman J, Stukus D, Rank MA, Wang J, Ellis A, Abrams E, Ledford D, Chu DK. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based

- recommendations. *Ann Allergy Asthma Immunol.* 2024 Mar;132(3):274-312. doi: 10.1016/j.anai.2023.11.009. Epub 2023 Dec 18. PMID: 38108679.
2. Bieber, T., Simpson, E. L., Silverberg, J. I., et al; JADE COMPARE Investigators. "Abrocitinib versus placebo or dupilumab for atopic dermatitis." *New England Journal of Medicine*, vol. 384, no. 12, 2021, pp. 1101-1112. doi:10.1056/NEJMoa2019380.
  3. Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. *J Am Acad Dermatol.* 2022 Jan;86(1):104-112. doi: 10.1016/j.jaad.2021.05.075. Epub 2021 Aug 17.
  4. Boguniewicz, M., Fonacier, L., Guttman-Yassky, E., Ong, P. Y., Silverberg, J., Farrar, J. R. "Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape." *Annals of Allergy, Asthma & Immunology*, vol. 120, no. 1, 2018, pp. 10-22.e2. doi: 10.1016/j.anai.2017.10.039. PMID: 29273118.
  5. Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J. Atopic dermatitis yardstick update. *Ann Allergy Asthma Immunol.* 2023 Jun; 130(6):811-820. doi:10.1016/j.anai.2023.03.010. Epub 2023 mar 16.
  6. Cibinqo (abrocitinib) [prescribing information]. New York, NY: Pfizer Labs; December 2023.
  7. Cork MJ, Deleuran M, Geng B, et al. Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age. *J Allergy Clin Immunol Pract.* 2025 May;13(5):1164-1175.e2. doi: 10.1016/j.jaip.2025.02.040. Epub 2025 Mar 11.
  8. Draelos, Z. D., Feldman, S. R., Berman, B., Olivadoti, M., Sierka, D., Tallman, A. M., ... & Baldwin, S. (2019). Tolerability of topical treatments for atopic dermatitis. *Dermatology and Therapy*, 9(1), 71-102.
  9. Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic Immunomodulatory Treatments for Patients with Atopic Dermatitis: A Systematic Review and Network Meta-analysis. *JAMA Dermatol.* 2020;156(6):659-667.
  10. Drucker AM, Lam M, Prieto-merino D. Systemic Immunomodulatory treatment for atopic dermatitis: living systemic review and network meta-analysis update. *JAMA Dermatol.* 2024;160(9):936-944. doi:10.1001/jamadermatol.2024.2192.
  11. Eichenfield, L. F., Flohr, C., Sidbury, R., et al. "Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial." *JAMA Dermatology*, vol. 157, no. 10, 2021, pp. 1165-1173. doi:10.1001/jamadermatol.2021.2830.
  12. Eichenfield, L. F., Tom, W. L., Berger, T. G., et al. "Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies." *Journal of the American Academy of Dermatology*, vol. 71, 2014, pp. 116-132. (Including potencies of topical corticosteroids).
  13. Mayo Clinic.org - Atopic Dermatitis. Available at: <https://www.mayoclinic.org/diseases-conditions/atopic-dermatitis-eczema>. Last Update June 2020. Accessed Feb 28, 2022.
  14. Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. *Lancet.* 2022 Jul 23;400(10348):273-282. doi: 10.1016/S0140-6736(22)01199-0.
  15. Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., O'Shea, J. J. "JAK inhibition as a therapeutic strategy for immune and inflammatory diseases." *Nature Reviews Drug Discovery*, vol. 17, no. 1, 2017, p. 78. doi:10.1038/nrd.2017.267.
  16. Seger, E. W., et al. "Relative efficacy of systemic treatments for atopic dermatitis." *Journal of the American Academy of Dermatology*, vol. 80, 2019, pp. 411. doi:10.1016/j.jaad.2018.09.053.
  17. Shi VY, Bhutani T, Fonacier L, et al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). *J Am Acad Dermatol.* 2022 Aug;87(2):351-358. doi: 10.1016/j.jaad.2022.04.009. Epub 2022 Apr 16.
  18. Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, Davis DMR. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. *J Am*

Acad Dermatol. 2023 Jul;89(1):e1-e20. doi: 10.1016/j.jaad.2022.12.029. Epub 2023 Jan 12. PMID: 36641009.

19. Silverberg, J. I., Simpson, E. L., Thyssen, J. P., et al. "Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial." *JAMA Dermatology*, vol. 156, no. 8, 2020, pp. 863-873. doi:10.1001/jamadermatol.2020.1406.
20. Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet*. 2020 Jul 25;396(10246):255-266. doi: 10.1016/S0140-6736(20)30732-7.
21. Sroka-Tomaszewska J, Trzeciak M. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. *Int J Mol Sci*. 2021 Apr 16;22(8):4130. doi: 10.3390/ijms22084130. PMID: 33923629; PMCID: PMC8074061.
22. Ständer S. Atopic Dermatitis. *N Engl J Med*. 2021 Mar 25;384(12):1136-1143. doi: 10.1056/NEJMra2023911. PMID: 33761208.
23. Thyssen JP, Bewley A, Ständer S, et al. Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis. *Dermatology*. 2024;240(2):243-253. doi: 10.1159/000535285. Epub 2023 Dec 11.
24. Wong, I. T., Tsuyuki, R. T., Cresswell-Melville, A., Doiron, P., & Drucker, A. M. (2017). Guidelines for the management of atopic dermatitis (eczema) for pharmacists. *Canadian Pharmacists Journal/Revue des Pharmaciens du Canada*, 150(5), 285-297.
25. Yew, Y. W., Thyssen, J. P., & Silverberg, J. I. (2019). A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. *Journal of the American Academy of Dermatology*, 80(2), 390-401.
26. Zheng Y, Ding RL, Bu J. Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review. *Front Immunol*. 2024 May 15;15:1367099. doi:10.3389/fimmu/2024.1367099.

#### Clinical Guideline Revision / History Information

Original Date: 03/17/2022

Reviewed/Revised: 06/29/2023, 12/19/2024, 11/01/2025